Writing the Biological Script: Scaling DNA Manufacturing for the Next Generation of Therapeutics

DNA synthesis is undergoing a structural transition from a laboratory capability to a key strategic industrial element within biopharmaceutical development. As advanced therapeutic modalities, including messenger RNA (mRNA), cell and gene therapies, and synthetic biology-derived products, continue to mature, the demands placed on DNA production have shifted toward consistency, scalability, and regulatory compliance. This article examines the evolving role of DNA synthesis within therapeutic manufacturing and the emergence of biofoundries as integrated production environments. The article highlights how the future of synthetic biology will depend not only on the ability to design biological systems, but on the capacity to manufacture DNA reliably at scale within regulated frameworks.

From Enabling Technology to Industrial Requirement

Over the past 2 decades, DNA synthesis has become a foundational capability in life sciences research, enabling the design and construction of genetic sequences for applications ranging from basic biology to drug discovery.¹ Yet, despite its importance, DNA synthesis has largely been treated as a supporting tool rather than a central component of industrial biopharmaceutical production.

Advanced therapies all share a common theme: using engineered biological systems to sense, and act in a more precise way than conventional drugs, finally bringing to fruition the decades-long promise of “programmable biology.” Indeed, as biology becomes increasingly programmable, this requires DNA to be considered throughout the entirety of discovery and development and embedded within the manufacturing processes of modern therapeutics.² DNA must not only be synthesized, but produced reproducibly, at scale, and in compliance with regulatory standards. The implications of this transition are significant, reframing DNA synthesis as an industrial discipline subject to the same constraints that have historically defined other areas of biopharmaceutical manufacturing.

The evolution of DNA synthesis mirrors earlier developments in biotechnology. Only after the development of scalable, reproducible manufacturing systems did the commercialization of monoclonal antibodies become possible.³ Over time, antibody production became standardized and integrated into regulated workflows.

A similar trajectory is emerging for DNA synthesis. Innovations such as enzymatic synthesis and novel assembly methods continue to advance the field (Figure 1). Now the central challenge has shifted toward manufacturing performance wherein DNA used in therapeutic applications must meet stringent requirements for sequence fidelity, purity, and traceability.⁴ Variability tolerated in research settings becomes unacceptable in clinical contexts, where inconsistencies can affect product safety and efficacy. As a result, DNA synthesis is increasingly evaluated through the lens of industrial robustness rather than purely technical capability.

The Changing Demands of Therapeutic Modalities

Modalities such as mRNA vaccines, viral vectors, and gene-editing therapies rely on precisely defined genetic constructs, making DNA a critical determinant of product quality.⁵

These applications are introducing new manufacturing requirements. DNA constructs are becoming longer and more complex, often incorporating multiple functional domains that must be assembled with high accuracy. At the same time, development timelines are compressing, particularly in areas such as personalized medicine and vaccine development, where rapid response, flexible manufacturing, and scalable production are increasingly important.⁶

Traditional synthesis approaches can struggle to meet these demands, particularly where sequences are long, complex, repetitive, or difficult to maintain consistently in biological production systems. In plasmid-based workflows, bacterial propagation introduces inherent biological variability, which can affect predictability, increase quality control requirements, and extend production timelines.

Cell-free production systems, including emerging enzymatic DNA synthesis (EDS) approaches, offer an alternative by reducing dependence on living host cells. By operating within programmable environments, these systems can provide greater sequence fidelity, more consistent performance across challenging constructs, and faster production workflows with reduced variability. This level of control is particularly attractive for applications requiring rapid iteration, reproducibility, and scalable manufacturing within regulated environments (Figure 2).

Consequently, there is growing interest in platforms capable of combining high fidelity, manufacturing flexibility, and scalable throughput to support the next generation of advanced therapeutics.

Biofoundries and “Labs in a Loop”

Biofoundries have emerged as a potential solution to the growing manufacturing demands associated with next-generation therapeutic modalities, while also representing an important evolution toward integrated, “lab-in-the-loop” development models that accelerate learning cycles from design to testing. Combining automation, robotics, software, and advanced cell-free enzymatic DNA synthesis technologies, these facilities enable high-throughput biological engineering and more agile development workflows.⁷

For emerging applications, such as personalized medicine, mRNA vaccines, cell and gene therapies, manufacturing requirements are changing. In these environments, timing, scalability, and sequence fidelity are increasingly crucial, often requiring smaller batch sizes, faster iteration cycles, and more flexible production capabilities than traditional manufacturing models were designed to support. Biofoundries platforms may therefore offer advantages for modern therapeutic development by enabling rapid, programmable, and potentially more localized manufacturing workflows.

By integrating design, build, and test processes, biofoundries can help reduce production timelines from months to days, improve development efficiency, and provide greater control over intellectual property and supply chains. Integration with digital systems and automated quality workflows may also support compliance with good manufacturing practice (GMP) requirements and improve manufacturing reproducibility within regulated environments.⁸

At the same time, established plasmid manufacturing approaches based on Escherichia coli (E. coli) fermentation remain the industry gold standard for many large-scale applications due to their maturity, scalability, and cost efficiency. Further, the establishment of in-house DNA manufacturing capabilities still requires significant investment in infrastructure, automation, and expertise.

As a result, the future manufacturing landscape is likely to be hybrid in nature, combining traditional centralized production systems with newer automated and cell-free manufacturing capabilities tailored to the requirements of advanced therapeutics.

Iteration, Control, and Development Cycles

The integration of DNA synthesis into development workflows has implications for how therapeutics are designed. Many modern platforms rely on iterative design–build–test cycles, where the speed and efficiency of iteration directly influence development outcomes.⁹

Closer integration of DNA production can reduce delays and enable more rapid experimentation. However, in regulated environments, this flexibility must be balanced with the need for documentation, validation, and reproducibility. Maintaining this balance represents a key challenge for organizations seeking to integrate synthesis capabilities more closely into development pipelines.

Redefining the Value of DNA Synthesis

While speed remains important, the value of DNA synthesis in modern biopharmaceutical manufacturing increasingly depends on quality, reproducibility, scalability, and regulatory compatibility. As advanced therapeutics such as mRNA vaccines, gene therapies, and cell therapies mature, DNA is no longer viewed as a standalone research reagent, but as a critical component of continuous manufacturing infrastructure.

This transition reflects the broader industrialization of DNA synthesis, driven by converging advances in synthesis technologies, rising therapeutic demand, and evolving regulatory expectations. Biofoundries and integrated production models may help address these needs; although, adoption will likely vary across applications and geographies. A hybrid ecosystem is expected to emerge, combining centralized manufacturing with selective in-house synthesis capabilities.

At the same time, biosecurity and governance frameworks will increasingly shape how DNA synthesis technologies are deployed globally, influencing both market structure and technological development.

Ultimately, DNA synthesis is evolving from a research-enabling technology into a foundational pillar of biopharmaceutical manufacturing. The future of synthetic biology will depend not only on advances in genetic design, but on the ability to manufacture DNA reliably, safely, and at industrial scale.

References

1. Kosuri S and Church GM. Large-scale de novo DNA synthesis: technologies and applications. Nature Methods, 2014; 11, 499–507.
2. Cameron DE, Bashor CJ, and Collins JJ. A brief history of synthetic biology. Nature Reviews Microbiology, 2014;12, 381–390.
3. Walsh G. Biopharmaceutical benchmarks 2018. Nature Biotechnology, 2018; 36, 1136–1145.
4. Hughes RA, and Ellington AD. Synthetic DNA synthesis and assembly. Cold Spring Harbor Perspectives in Biology, 2017; 9(1).
5. Pardi N, et al. mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 2018; 17, 261–279.
6. Jackson NAC, et al. The promise of mRNA vaccines. NPJ Vaccines, 2020; 5, 11.
7. Chao R, et al. Engineering biological systems using automated biofoundries. Metabolic Engineering, 2017; 42, 98–108.
8. FDA. Guidance for Industry: CGMP for Phase 1 Investigational Drugs. 2020.
9. Carbonell P, et al. An automated Design-Build-Test-Learn pipeline for enhanced microbial production of fine chemicals. Communications Biology, 2018; 10, 1007.

About the Author

Dr. Thomas Ybert is chief scientific officer and co-founder of DNA Script and leads the company's research and innovation efforts. Thomas is the main inventor of DNA Script's Enzymatic DNASynthesis (EDS) technology. Holding a PhD in molecular biology and yeast genetics from Ecole Polytechnique, his background includes R&D roles at Sanofi and Total/Amyris.